




Fig. S1. Levels of the chemokines CXCL8, CXCL9, CXCL10, CXCL11, CCL17, CCL20 and CCL22 measured in the plasma of patients with psoriasis before (0 wks) and after 6 (ultraviolet B (UVB) 6 wks) and 12 weeks (UVB 12 wks) of narrowband UVB therapy, $n=15$.




Fig. S2. The levels of the cytokines interleukin (IL)-1 β , IL-10, IL-12p(70) and IL-23 in cell culture supernatant from lipopolysaccharide (LPS)-activated peripheral blood mononuclear cells from patients with psoriasis before (Psoriasis LPS 0 wks) and 12 weeks after narrowband ultraviolet B (UVB) therapy (Psoriasis LPS 12 wks) and from healthy controls (Healthy LPS). The line shows the median, $n = 10$.




Fig. S3. Levels of the chemokine CCL20 in cell culture supernatant from lipopolysaccharide (LPS)-activated (a) or anti-CD3- and anti-CD28-activated (b) peripheral blood mononuclear cells from patients with psoriasis before (Psoriasis 0 wks) and 12 weeks after narrowband ultraviolet B (UVB) therapy (Psoriasis 12 wks) and from their matched, healthy controls. The line shows the median, $n=10$.